.

EVENTS

home.aspx
   
2nd Annual Congress on Cellular Therapies, Cancer, Stem Cells and Bio Medical Engineering
2ND ANNUAL CONGRESS ON CELLULAR THERAPIES, CANCER, STEM CELLS AND BIO MEDICAL ENGINEERING
July 17-18, 2020
Cellulartherapies 2020 main goal is to deliver ideal treatment methods and advance research studies information. Through focus on the anticipation, analysis of Cancer, as well as related Cancer Genetics, Pathophysiology, Epidemiology, Chemotherapy, Clinical Reports, Cancer Biology, Cellular Therapy,...

9th World Congress on Human Genetics and Genetic Diseases
9TH WORLD CONGRESS ON HUMAN GENETICS AND GENETIC DISEASES
August 10-11, 2020
Human Genetics 2020 Conferences offers the scientific community a platform to share their knowledge in the field of Human Genetics and Genetic Diseases. This conference offers a comprehensive agenda presented through two plenary sessions and panel discussions for the benefit of professionals in the ...

Biotechnology and Biomaterials
BIOTECHNOLOGY AND BIOMATERIALS
August 20-21, 2020
The key intention of Biotechnology and Biomaterials-2020 is to provide opportunity for the global participants to share their ideas and experience in person with their peers expected to join from different parts on the world.

Cell Biology 2020
CELL BIOLOGY 2020
September 23-23, 2020
Cell Biology 2020 Virtual Event will continue to create a valuable platform for inspiring global and interdisciplinary collaboration in a virtual environment, to study cells cells – their physiological properties, structure, the organelles they contain, environmental interactions, life cycle, ...

24th European Biotechnology Congress
24TH EUROPEAN BIOTECHNOLOGY CONGRESS
September 23-24, 2020
European Biotechnology Congress is the world’s leading conference for all professionals to gather and contribute their research. Euro Biotechnology offers over 24 sessions from different areas in the field of Biotechnology in the form of Keynote, Plenary and workshop sessions including oral an...

2nd International Conference on Genetics and Molecular Biology
2ND INTERNATIONAL CONFERENCE ON GENETICS AND MOLECULAR BIOLOGY
September 24-25, 2020
Molecular Biology 2020 can provide an ideal platform to all or any the Scientists, Researchers, Students and Business Delegates to approach and deliver all the attendees concerning the most recent scientific advancements on the several spheres.

Industrial Microbiology Meets the Microbiome
INDUSTRIAL MICROBIOLOGY MEETS THE MICROBIOME
November 08-10, 2020
The goal of the meeting is to bring together academics, industrial scientists, technology providers and regulators in studying and manipulating the microbiome in industrial settings such as agriculture, household care, built environment, personal care, animal health, and nutrition. Recent results of...

FT Global Pharmaceutical and Biotechnology Conference 2020
FT GLOBAL PHARMACEUTICAL AND BIOTECHNOLOGY CONFERENCE 2020
November 09-10, 2020
The global pharma industry is at a turning point in its transformation. After years of research, the field of advanced cell and gene therapies is achieving new landmarks, and the reality of curative therapies is here. The focus on molecular targets is opening up new possibilities for research, with ...

SPOTLIGHT

Cell Biology 2020 Virtual Event will continue to create a valuable platform for inspiring global and interdisciplinary collaboration in a virtual environment, to study cells cells – their physiological properties, structure, the organelles they contain, environmental interactions, life cycle,

SEP 16, 2020 | 6:00am
MICROBIOLOGY & IMMUNOLOGY 2020
Microbiology and Immunology cover an array of industries and disciplines, encompassing various research areas including pharmaceuticals, medicine, agriculture, and space. The development of new techniques and the ability to sequence organisms without the need to grow them in the laboratory has opene...
SEP 23, 2020
CELL BIOLOGY 2020
Cell Biology 2020 Virtual Event will continue to create a valuable platform for inspiring global and interdisciplinary collaboration in a virtual environment, to study cells cells – their physiological properties, structure, the organelles they contain, environmental interactions, life cycle, ...
SEP 30, 2020
CRISPR 2020
This event will continue the conversation of the abilities of CRISPR-based editing, next-gen editing tools, precision in gene editing and using CRISPR for drug discovery.
OCT 07, 2020
C RESEARCH & ONCOLOGY 2020
This event will focus on advancements in prevention, diagnosis and treatment of different cancer types.
ADDRESSING THE CHALLENGES IN MAINTAINING AND ANALYZING BIOTHERAPEUTIC GLYCOSYLATION
As the market for biopharmaceuticals continues to grow, manufacturers are increasingly challenged to improve their process efficiency while maintaining in vivo safety and efficacy profiles. Foremost of those challenges is minimization of batch-to-batch variability in product profile. Heterogeneous g...
FDA REGULATION OF HUMAN CELLS, TISSUES AND CELLULAR AND TISSUE-BASED PRODUCTS
Companies manufacturing products derived from human cells and tissues for autologous implantation, transplantation, infusion or transfer of human cells and tissues for therapeutic purposes are allowed to market their products without a formal marketing approval under a BLA provided they meet certain...
USING MICROPATTERNED CO-CULTURES TO MODEL HUMAN-SPECIFIC DRUG METABOLISM, DISPOSITION AND DRUG-DRUG INTERACTIONS
Webinar was presented on 10 March, 2016 by Dr. Salman Khetani, Associate Professor, Department of Bioengineering, University of Illinois at Chicago, USAIn this webinar, Dr Salman described how micropatterned co-cultures (MPCCs) containing cryopreserved hepatocytes in industry-standard multi-well pla...
ENGINEERING MICROPATTERNED CO-CULTURES FOR DRUG DEVELOPMENT
Due to significant differences across species in liver pathways, models of the human liver are used to screen for potential efficacy and/or toxicity of candidate compounds. Such models serve to complement and reduce the number of animals used in studies required by regulatory agencies. However, once...
THE UTILITY OF MICROSCALE HUMAN LIVER CO-CULTURES FOR INVESTIGATING DRUG TOXICITY OUTCOMES
Drug-induced liver injury (DILI) remains a leading cause of acute liver failures and the attrition of pharmaceuticals in both preclinical and clinical settings. Due to species-specific differences in drug metabolism pathways, animal models do not always fully predict human DILI. Thus, there is a nee...
COMBINING TRANSPORTER DATA WITH QUANTITATIVE SYSTEMS TOXICOLOGY MODELING (DILISYM) TO IMPACT DECISIONS IN DRUG DEVELOPMENT
A quantitative systems toxicology (QST) model of drug-induced liver injury (DILI) has been developed through the DILI-sim Initiative over the past 7 years to assist in the safety characterization of compounds in clinical development. The emerging platform, DILIsym®, is capable of predicting and ...
THE POTENTIAL OF ENGINEERED HUMAN LIVER CO-CULTURES IN PHENOTYPIC DRUG DISCOVERY FOR LIVER DISEASES
The diverse functions of the liver (i.e. albumin synthesis, glucose and fatty acid metabolism, drug metabolism) can be severely compromised by several diseases. In particular, drug-induced liver injury is a leading cause of drug attrition; hepatitis B virus chronically infects the livers of ~400 mil...
WIPR AND BSKB PRESENT: OBVIOUSNESS IN PTAB TRIALS FOR CHEM/PHARMA/BIO PATENTS.
Challenging patents involving unpredictable technologies for obviousness is particularly difficult due to the well-established factor of “reasonable expectation of success” and the related KSR factor of “limited number of predictable solutions”. This webinar, presented by att...
THE TRUTH ABOUT DELIVERING CLINICAL RESEARCH IN THE UK?
Over the last seven years the research landscape in the UK has improved dramatically allowing the UK to make great strides in delivering research for the Life Sciences industry. So whether you are a Pharmaceutical Company, Contract Research Organisation, Biotech, Med Tech or Diagnostic company we ca...
DEVELOPING MEDICAL EDUCATION THAT ADVANCES PATIENT OUTCOMES.
As pressure mounts on the pharmaceutical industry to demonstrate a tangible and positive impact on patients’ lives, understanding barriers to specific clinician behaviours is key to achieving measurable change in clinical practice and advancing patient outcomes.
ESTABLISHING FERTILITY BIOMARKERS
The adult mammalian ovary contains thousands of oocytes, yet only very few will be ovulated and able to support embryonic development until birth. Why are so many oocytes eliminated? What makes an oocyte of good or bad quality? With approximately 15% of couples of reproductive age needing assisted r...
MONITORING PRODUCT AND PROCESS ATTRIBUTES IN BIOPHARMACEUTICAL DEVELOPMENT AND QC
Across biopharmaceutical development, LC-MS has been a foundational technology for the discovery and characterization of biotherapeutic attributes—including post-translational modifications such as glycosylation, oxidation, and deamidation, as well as process impurities such as host cell prote...